Pharmacotherapy for the treatment of obesity

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 173-183

  Sweeting, Arianne N ^a,b,c   Hocking, Samantha L ^d   Markovic, Tania P ^a,b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Obesity; Pharmacotherapy; Review

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; BELORANIB; CANNABINOID 1 RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRABEGRON; NEUROPEPTIDE Y5 RECEPTOR; PHENTERMINE; PLACEBO; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ARTICLE; BARIATRIC SURGERY; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HUMAN; HYPOGLYCEMIA; INSOMNIA; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA AND VOMITING; OBESITY; PARESTHESIA; PRIORITY JOURNAL; TREATMENT DURATION; WEIGHT REDUCTION; XEROSTOMIA; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; DRUG EFFECTS; NEUROSECRETION;

ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; NEUROSECRETORY SYSTEMS; OBESITY;

EID: 84951568463     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.09.005     Document Type: Article

References (101)

1. Agerso H., Jensen L.B., Elbrond B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45(2):195-202.
2. Allison D.B., Gadde K.M., Garvey W.T., Peterson C.A., Schwiers M.L., Najarian T., et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012, 20(2):330-342.
3. Apovian C.M., Aronne L., Rubino D., Still C., Wyatt H., Burns C., et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013, 21(5):935-943.
4. Arch J.R. Challenges in beta(3)-adrenoceptor agonist drug development. Ther. Adv. Endocrinol. Metab. 2011, 2(2):59-64.
5. Arora S., Anubhuti Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 2006, 40(6):375-401.
6. Astrup A., Rossner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374(9701):1606-1616.
7. Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E., et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 2012, 36(6):843-854.
8. Bays H.E. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev. Cardiovasc. Ther. 2009, 7(11):1429-1445.
9. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 2003, 11(4):556-562.
10. Billes S.K., Greenway F.L. Combination therapy with naltrexone and bupropion for obesity. Expert Opin. Pharmacother. 2011, 12(11):1813-1826.
11. Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta 1988, 962(3):308-316.
12. Braga M.F., Aroniadou-Anderjaska V., Li H., Rogawski M.A. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J. Pharmacol. Exp. Ther. 2009, 330(2):558-566.
13. Brandes J.L., Saper J.R., Diamond M., Couch J.R., Lewis D.W., Schmitt J., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004, 291(8):965-973.
14. Cawthorne M.A., Sennitt M.V., Arch J.R., Smith S.A. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. Am. J. Clin. Nutr. 1992, 55(Suppl. l):252S-257S.
15. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370(9600):1706-1713.
16. Cluny N.L., Chambers A.P., Vemuri V.K., Wood J.T., Eller L.K., Freni C., et al. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav. 2011, 97(3):537-543.
17. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 2005, 8(5):571-578.
18. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337(9):581-588.
19. Cypess A.M., Weiner L.S., Roberts-Toler C., Elia E.F., Kessler S.H., Kahn P.A., et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015, 21(1):33-38.
20. Douglas A.D.J., Robertson C.E., Munro J.F. Plasma phentermine levels, weight loss and side-effects. Int. J. Obes. 1983, 7(6):591-595.
21. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372(9645):1240-1250.
22. Eckel R.H. Clinical practice. Nonsurgical management of obesity in adults. N. Engl. J. Med. 2008, 358(18):1941-1950.
23. FDA Approves Weight-management Drug Contrave 10 September 2014, [press release]. US.
24. FDA Approves Weight-management Drug Saxenda 23 December 2014, [press release]. US.
25. Fidler M.C., Sanchez M., Raether B., Weissman N.J., Smith S.R., Shanahan W.R., et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 2011, 96(10):3067-3077.
26. Finan B.Y.B., Ottaway N., Smiley D.L., Ma T., Clemmensen C., Chabenne J., Zhang L., Habegger K., Fischer K., Campbell J.E., Sandoval D., Seeley R., Bleicher K., Uhles S., Riboulet W., Funk J., Hertel C., Belli S., Sebokova E., Conde-Knape K., Konkar A., Drucker D.J., Gelfanov V., Pfluger P.T., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 2015, 21:27-36.
27. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Investig. 1998, 101(3):515-520.
28. Flint A., Raben A., Ersboll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metabol. Disord. 2001, 25(6):781-792.
29. Gadde K.M., Allison D.B., Ryan D.H., Peterson C.A., Troupin B., Schwiers M.L., et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9774):1341-1352.
30. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373(9662):473-481.
31. Garvey W.T., Ryan D.H., Look M., Gadde K.M., Allison D.B., Peterson C.A., et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 2012, 95(2):297-308.
32. George M., Rajaram M., Shanmugam E. New and emerging drug molecules against obesity. J. Cardiovasc. Pharmacol. Ther. 2014, 19(1):65-76.
33. Gershberg H.K.R., Hulse M., Pengsen E. Effects of diet and an anorectic drug (phentermine resin) in obese diabetics. Curr. Ther. Res. 1977, 22:814-820.
34. Goldstein M.G. Bupropion sustained release and smoking cessation. J. Clin. Psychiatry 1998, 59(Suppl. 4):66-72.
35. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009, 17(1):30-39.
36. Greenway F.L., Fujioka K., Plodkowski R.A., Mudaliar S., Guttadauria M., Erickson J., et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376(9741):595-605.
37. Haddock C.K., Poston W.S., Dill P.L., Foreyt J.P., Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metabolic Disord. 2002, 26(2):262-273.
38. Heal D.J., Gosden J., Smith S.L. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol. 2009, 68(6):861-874.
39. Hendricks E.J., Greenway F.L. A study of abrupt phentermine cessation in patients in a weight management program. Am. J. Ther. 2011, 18(4):292-299.
40. Hendricks E.J., Greenway F.L., Westman E.C., Gupta A.K. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity 2011, 19(12):2351-2360.
41. Hendricks E.J., Srisurapanont M., Schmidt S.L., Haggard M., Souter S., Mitchell C.L., et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int. J. Obes. 2014, 38(2):292-298.
42. Hollander P., Gupta A.K., Plodkowski R., Greenway F., Bays H., Burns C., et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013, 36(12):4022-4029.
43. Hunt S., Russell A., Smithson W.H., Parsons L., Robertson I., Waddell R., et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 71(4):272-276.
44. Isidro M.L., Cordido F. Drug treatment of obesity: established and emerging therapies. Mini Rev. Med. Chem. 2009, 9(6):664-673.
45. James W.P., Caterson I.D., Coutinho W., Finer N., Van Gaal L.F., Maggioni A.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 2010, 363(10):905-917.
46. Kang J.G., Park C.Y., Kang J.H., Park Y.W., Park S.W. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes, Obes. Metab. 2010, 12(10):876-882.
47. Kelley D.E., Kuller L.H., McKolanis T.M., Harper P., Mancino J., Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004, 27(1):33-40.
48. Khanna V., Arumugam S., Roy S., Mittra S., Bansal V.S. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin. Ther. Targets 2008, 12(1):81-90.
49. Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP2) Inhibitor, Appeared Safe and Showed Significant Body Weight Loss over 12 Weeks in a Phase 2 Study 2013, The Obesity Society Obesity Week, Atlanta. D.D. Kim, J. Krishnarajah, S. Lilloja, J. Marjason, J. Proietto, S. Shakib, B. Stuckey, A. Chen, J.E. Vath, T.E. Hughes (Eds.).
50. Kral J.G., Naslund E. Surgical treatment of obesity. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3(8):574-583.
51. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2(8571):1300-1304.
52. Larsen T.M., Toubro S., van Baak M.A., Gottesdiener K.M., Larson P., Saris W.H., et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am. J. Clin. Nutr. 2002, 76(4):780-788.
53. Li Z., Maglione M., Tu W., Mojica W., Arterburn D., Shugarman L.R., et al. Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 2005, 142(7):532-546.
54. Lorello C., Goldfield G.S., Doucet E. Methylphenidate hydrochloride increases energy expenditure in healthy adults. Obes. Silver Spring 2008, 16(2):470-472.
55. Maggio C.A., Presta E., Bracco E.F., Vasselli J.R., Kissileff H.R., Pfohl D.N., et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res. Bull. 1985, 14(6):657-661.
56. Malik V.S., Willett W.C., Hu F.B. Global obesity: trends, risk factors and policy implications. Nat. Rev. Endocrinol. 2013, 9(1):13-27.
57. Mark E.J., Patalas E.D., Chang H.T., Evans R.J., Kessler S.C. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N. Engl. J. Med. 1997, 337(9):602-606.
58. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49(3):452-458.
59. Miller W.C., Koceja D.M., Hamilton E.J. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int. J. Obes. Relat. Metab. Disord. 1997, 21(10):941-947.
60. Munro J.F., MacCuish A.C., Wilson E.M., Duncan L.J. Comparison of continuous and intermittent anorectic therapy in obesity. Br. Med. J. 1968, 1(5588):352-354.
61. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60(5):1561-1565.
62. Neoh S.L., Sumithran P., Haywood C.J., Houlihan C.A., Lee F.T., Proietto J. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med. J. Aust. 2014, 201(4):224-226.
63. NHRMC Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults 2013, Adolescents and Children in Australia, Melbourne.
64. O'Neil P.M., Smith S.R., Weissman N.J., Fidler M.C., Sanchez M., Zhang J., et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obes. Silver Spring 2012, 20(7):1426-1436.
65. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. 2003, 27(12):1437-1446.
66. Pasquali R.C.F., Melchionda N., et al. Effects of chronic administration of ephidrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin. Sci. Lond 1992, 82(1):85-92.
67. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006, 30(Suppl. 1):S13-S18.
68. Picard F., Deshaies Y., Lalonde J., Samson P., Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 2000, 8(9):656-663.
69. Pratley R.E., Nauck M.A., Barnett A.H., Feinglos M.N., Ovalle F., Harman-Boehm I., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes & Endocrinol. 2014, 2(4):289-297.
70. Pyke C., Heller R.S., Kirk R.K., Orskov C., Reedtz-Runge S., Kaastrup P., et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155(4):1280-1290.
71. Randall P.A., Vemuri V.K., Segovia K.N., Torres E.F., Hosmer S., Nunes E.J., et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol. Biochem. Behav. 2010, 97(1):179-184.
72. Redman L.M., de Jonge L., Fang X., Gamlin B., Recker D., Greenway F.L., et al. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J. Clin. Endocrinol. Metabol. 2007, 92(2):527-531.
73. Robert M. Clinical briefing document. Endocrinologic and Metabolic Drugs Advisory Comittee Meeting for Phentermine/topiramate (Qnexa) 2010.
74. Rodgers R.J., Tschop M.H., Wilding J.P. Anti-obesity drugs: past, present and future. Dis. Models Mech. 2012, 5(5):621-626.
75. Rossner S., Sjostrom L., Noack R., Meinders A.E., Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. 2000, 8(1):49-61.
76. Rothman R.B., Baumann M.H. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf. 2009, 8(3):317-329.
77. Rueda-Clausen C.F., Padwal R.S., Sharma A.M. New pharmacological approaches for obesity management. Nat. Rev. Endocrinol. 2013, 9(8):467-478.
78. Samat A., Tomlinson B., Taheri S., Thomas G.N. Rimonabant for the treatment of obesity. Recent Pat. Cardiovasc. Drug Discov. 2008, 3(3):187-193.
79. Secher A., Jelsing J., Baquero A.F., Hecksher-Sorensen J., Cowley M.A., Dalboge L.S., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Investig. 2014, 124(10):4473-4488.
80. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl. 1):S3-S9.
81. Sisley S., Gutierrez-Aguilar R., Scott M., D'Alessio D.A., Sandoval D.A., Seeley R.J. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Investig. 2014, 124(6):2456-2463.
82. Sjostrom L., Narbro K., Sjostrom C.D., Karason K., Larsson B., Wedel H., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 2007, 357(8):741-752.
83. Smith S.R., Weissman N.J., Anderson C.M., Sanchez M., Chuang E., Stubbe S., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 2010, 363(3):245-256.
84. Sumithran P., Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin. Sci. Lond 2013, 124(4):231-241.
85. Sumithran P., Prendergast L.A., Delbridge E., Purcell K., Shulkes A., Kriketos A., et al. Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 2011, 365(17):1597-1604.
86. Sweeting A.N., Tabet E., Caterson I.D., Markovic T.P. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes, Metab. Syndr. Obes. 2014, 7:35-44.
87. Takasu T., Ukai M., Sato S., Matsui T., Nagase I., Maruyama T., et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-2-[(2-hydroxy-2-phenylethyl)amino]ethyl acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J. Pharmacol. Exp. Ther. 2007, 321(2):642-647.
88. Tonstad S., Tykarski A., Weissgarten J., Ivleva A., Levy B., Kumar A., et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am. J. Cardiol. 2005, 96(2):243-251.
89. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27(1):155-161.
90. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 2001, 86(9):4382-4389.
91. Verrotti A., Scaparrotta A., Agostinelli S., Di Pillo S., Chiarelli F., Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011, 95(3):189-199.
92. Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courreges J.P., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1608-1610.
93. Wadden T.A., Foreyt J.P., Foster G.D., Hill J.O., Klein S., O'Neil P.M., et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011, 19(1):110-120.
94. Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int. J. Obes. 2013, 37(11):1443-1451.
95. Weintraub M., Hasday J.D., Mushlin A.I., Lockwood D.H. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 1984, 144(6):1143-1148.
96. Weyer C., Tataranni P.A., Snitker S., Danforth E., Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998, 47(10):1555-1561.
97. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996, 81(1):327-332.
98. Wimmelmann C.L., Dela F., Mortensen E.L. Psychological predictors of mental health and health-related quality of life after bariatric surgery: a review of the recent research. Obes. Res. Clin. Pract. 2014, 8(4):e314-e324.
99. World Health Organisation Scientific background papers of the joint WHO/FAO expert consultation, Geneva, 28 January - 1 February 2002. Public Health Nutr. 2004, 7(1(A) Suppl. 1001):99-100.
100. Yanovski S.Z., Yanovski J.A. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2013, 311(1):74-86.
101. Zafgen Announces Positive Results from Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity [press Release]. Boston, Massuchussets, 7 January 2015 7 January 2015.